Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Upgraded by Barclays to “Strong-Buy” Rating

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was upgraded by investment analysts at Barclays to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Swedish Orphan Biovitrum AB (publ) Price Performance

Shares of OTCMKTS BIOVF opened at $28.30 on Wednesday. The firm’s 50-day moving average is $28.88 and its two-hundred day moving average is $28.35. The company has a market capitalization of $10.07 billion, a PE ratio of 47.97 and a beta of 0.51. Swedish Orphan Biovitrum AB has a 12-month low of $22.87 and a 12-month high of $32.25. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.73 and a quick ratio of 0.49.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.